Compass Therapeutics (NASDAQ:CMPX – Get Free Report) is anticipated to release its earnings data before the market opens on ...

In this article, we are going to take a look at where Compass Therapeutics, Inc. (NASDAQ:CMPX) stands against the other ...

Compass Therapeutics, Inc.’s CMPX share price has dipped by 11.90%, which has investors questioning if this is right time to buy.

Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Free Report) has earned an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the firm, Ratings reports. Two analysts ...

In this article, we are going to take a look at where Compass Therapeutics, Inc. (NASDAQ:CMPX) stands against the other biotech stocks. No matter the market environment, you’ll always find ...

Fintel reports that on February 24, 2025, Guggenheim initiated coverage of Compass Therapeutics (NasdaqCM:CMPX) with a Buy recommendation. Analyst Price Forecast Suggests 266.05% Upside As of February ...

Financially, CMPX has a market cap of $423mn, a cash balance of $135mn, and a cash runway of 10-11 quarters, ensuring sufficient funding. The BTC market is small and competitive, with existing ...

The firm increased its portfolio allocation in CMPX by 13.25% over the last quarter. Enavate Sciences GP holds 7,788K shares representing 5.66% ownership of the company. Adage Capital Partners Gp ...

Shares of Compass Therapeutics (NASDAQ:CMPX) were up 8% in afternoon trading Monday after Guggenheim initiated coverage of the stock with a buy rating ahead of upcoming data for the company's drug ...

Compass Therapeutics Inc (NASDAQ:CMPX) is a biopharmaceutical company that makes antibody-based therapies for several diseases. The stock is up significantly so far in 2025 due to it reporting ...